Navigation Links
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Date:2/8/2010

HAYWARD, Calif., Feb. 8 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome. This pivotal study, which is expected to begin in the first half of this year and to be completed 18 months thereafter, is expected to enroll up to 6,500 patients. Patients will be randomized within 96 hours of an acute coronary syndrome and will receive 16 weeks of either once-daily of A-002 or placebo in addition to a dose of atorvastatin.

In addition, Anthera today announced that it has appointed Daniel K. Spiegelman to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors.  Mr. Spiegelman provides management and financial consulting services to biotechnology companies. From 1998 to 2009, Mr. Spiegelman served as Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company that was acquired by Gilead Sciences, Inc. in 2009. From 1991 to 1998, Mr. Spiegelman served at Genentech, Inc., most recently as Treasurer. Mr. Spiegelman also serves on the board of directors of Affymax, Inc., Cyclacel Pharmaceuticals, Inc., Omeros Corporation and Oncothyreon, Inc., all publicly traded biopharmaceutical companies. Mr. Spiegelman holds a B.A. in economics from Stanford University and
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
2. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
4. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
5. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
7. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
8. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
11. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. ... CVS ), will speak before the National Press Club ... discuss the company,s recent move to stop selling tobacco products ... the future of health. "Dramatic changes in our ... care providers and government," Merlo has said. "CVS Health has ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
(Date:9/21/2014)... NY (PRWEB) September 21, 2014 The ... help businesses and manufacturers perform tests on items ranging ... an increasingly regulated society, pressure on operators to ensure ... than ever. A greater number of government safety regulations ... manufacturers' goods prior to sale. Although revenue briefly dipped ...
(Date:9/21/2014)... September 22, 2014 The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ... and ICS/LABA therapies delivered by the next-generation inhalers ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... Discount-Dress.com, a company that ... announced its decision to implement a new shopping cart ... ladies across the world. Furthermore, the company has unveiled ... , The new items come in fashionable designs; ... up to 56 percent off. "We are happy to ...
(Date:9/21/2014)... Rio, Colorado (PRWEB) September 21, 2014 ... Colorado, ten teams of disabled and able-bodied athletes rafted ... and completed a ropes course in pursuit of outdoor ... from national non-profit World T.E.A.M. Sports, disabilities proved ... athletes who successfully completed the three stage event. , ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... smoke. According to a recent study researchers find smoking during ... having a baby with a cleft lip. ,The study, ... their babies were about six months old. Researchers asked about ... many cigarettes she smoked and whether she was exposed to ...
... of osteoarthritis the major cause of disability in ... a few weeks // say researchers according to ... in Europe and the United States recommend the ... to relieve osteoarthritis pain. ,Researchers explain many ...
... could be the first step in the path for a ... first time they have found a successful way to deliver ... mouse. ,Gene therapy for muscular dystrophy has been ... the whole body has been a major obstacle for scientists. ...
... drug for the treatment of alcohol dependence. But one of ... which can reduce medication compliance and can be absorbed // ... injection of naltrexone and the benefit of its use for ... they were randomly assigned to get an injection of naltrexone ...
... clinical trial of people infected with both HIV and hepatitis ... their study, patients who are treated with a newer combination ... of HCV than those who receive standard therapy. ,The ... estimated 1 million Americans infected with HIV also have HCV, ...
... low-fat salad dressing anymore. New research shows fats actually ... ,Researchers studied men and women between ages 19 ... with salad dressing that contained zero, six or 28 ... 11 hours following each meal. ,Results showed that ...
Cached Medicine News:
... LH Ovulation Predicting Test is a qualitative ... Hormone (hLH) in human urine to predict ... by the elevation of human luteinizing hormone ... period starts, hLH has a brief, significant ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... The Shandon Varistain 24-4 ... stainer designed to offer simplicity ... cytology staining applications. It is ... load and continuous throughput. ...
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: